NASDAQ:ISRG • US46120E6023
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INTUITIVE SURGICAL INC (ISRG).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Citigroup | Upgrade | Neutral -> Buy |
| 2026-02-24 | UBS | Maintains | Neutral -> Neutral |
| 2026-01-27 | Freedom Capital Markets | Upgrade | Hold -> Buy |
| 2026-01-27 | TD Cowen | Initiate | Buy |
| 2026-01-26 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-23 | Bernstein | Maintains | Outperform -> Outperform |
| 2026-01-23 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-23 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-01-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-23 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-09 | Bernstein | Maintains | Outperform -> Outperform |
| 2026-01-07 | BTIG | Maintains | Buy -> Buy |
| 2026-01-07 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-18 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-11 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-10-23 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-22 | BTIG | Maintains | Buy -> Buy |
| 2025-10-22 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-22 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-22 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-10-22 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-22 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-15 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-13 | BTIG | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.124B 14.49% | 8.352B 17.24% | 10.065B 20.51% | 11.749B 16.73% | 13.377B 13.86% | 15.249B 13.99% | 16.629B 9.05% | 18.599B 11.85% | 19.798B 6.45% | 21.714B 9.68% | 23.836B 9.77% | |
| EBITDA YoY % growth | 2.235B 12.33% | 2.856B 27.80% | 3.632B 27.17% | 5.059B 39.27% | 5.754B 13.74% | 6.706B 16.55% | 7.58B 13.03% | 8.274B 9.16% | N/A | N/A | N/A | |
| EBIT YoY % growth | 1.78B 11.45% | 2.357B 32.38% | 2.955B 25.40% | 4.376B 48.07% | 5.034B 15.04% | 5.8B 15.22% | 6.741B 16.22% | 7.641B 13.35% | N/A | N/A | N/A | |
| Operating Margin | 24.99% | 28.22% | 29.36% | 37.25% | 37.63% | 38.04% | 40.54% | 41.08% | N/A | N/A | N/A | |
| EPS YoY % growth | 5.71 21.75% | 7.33 28.37% | 8.93 21.83% | 10.22 14.45% | 11.68 14.24% | 13.41 14.88% | 14.99 11.79% | 16.88 12.56% | 18.63 10.35% | 19.92 6.96% | 21.51 7.99% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.16 19.10% | 2.53 15.50% | 2.54 5.75% | 2.67 5.44% | 2.47 14.62% | 2.66 5.25% | 2.57 1.28% | 3.01 12.79% |
| Revenue Q2Q % growth | 2.672B 18.58% | 2.852B 16.89% | 2.911B 16.20% | 3.159B 10.22% | 2.998B 12.20% | 3.187B 11.75% | 3.216B 10.48% | 3.523B 11.52% |
| EBITDA Q2Q % growth | 1.071B 46.05% | 1.255B 18.44% | 1.255B 0.94% | 1.317B -14.59% | 1.293B 20.73% | 1.364B 8.69% | 1.387B 10.52% | 1.491B 13.21% |
| EBIT Q2Q % growth | 899.58M 54.12% | 1.075B 44.18% | 1.097B 44.40% | 1.153B 33.31% | 1.089B 21.06% | 1.192B 10.88% | 1.224B 11.58% | 1.348B 16.91% |
All data in USD
42 analysts have analysed ISRG and the average price target is 624.51 USD. This implies a price increase of 32.27% is expected in the next year compared to the current price of 472.16.
INTUITIVE SURGICAL INC (ISRG) will report earnings on 2026-04-20, after the market close.
The consensus EPS estimate for the next earnings of INTUITIVE SURGICAL INC (ISRG) is 2.16 USD and the consensus revenue estimate is 2.67B USD.
The number of analysts covering INTUITIVE SURGICAL INC (ISRG) is 42.